Loading
A phase 3 trial of Darolutamide in prostate cancer, run by Bayer, active and no longer recruiting.
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies is a phase 3 interventional study registered as NCT05794906 by Bayer, with 985 participants enrolled, started 2023-04-03 and due to reach its primary completion in 2027-07-30. Interventions recorded: Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT. Conditions listed: Biochemically Recurrent Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Darolutamide, Bayer, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Bayer, Androgen deprivation & AR pathway inhibitors.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Prostate cancer.
Shares Biochemical recurrence of prostate cancer, Prostate cancer.